Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes

被引：0
|
作者：
Ambery, Philip
Stumvoll, Michael W.
Posch, Maximilian G.
Heise, Tim
Plum-Moerschel, Leona
Tsai, Lan-Feng
Robertson, Darren
Petrone, Marcella
Rondinone, Cristina
Parker, Victoria E.
Hirshberg, Boaz
Jermutus, Lutz
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1067-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
    Ambery, Philip D.
    Klammt, Sebastian
    Posch, Maximillian G.
    Petrone, Marcella
    Pu, Wenji
    Rondinone, Cristina
    Jermutus, Lutz
    Hirshberg, Boaz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (10) : 2325 - 2335
  • [22] Effect of MEDI0382, a Glucagon-like Peptide 1/Glucagon Receptor Dual Agonist, on Hepatic Fat and Relationship to Metabolomic Changes in Overweight or Obese Subjects with Type 2 Diabetes Mellitus
    Jain, Meena
    Trevaskis, James
    Boland, Michelle L.
    Conway, James
    Tsai, Lan-Feng
    Hirshberg, Boaz
    Jermutus, Lutz
    Ambery, Philip
    HEPATOLOGY, 2018, 68 : 436A - 437A
  • [23] MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Acutely Inhibits Food Intake in Leptin-Deficient ob/ob Mice and Leptin Receptor-Deficient fa/fa Rats
    Howard, Victor G.
    Oldham, Stephanie
    Konkar, Anish
    Trevaskis, James
    Will, Sarah
    DIABETES, 2018, 67
  • [24] Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus
    Lahey, Alexa M.
    Duprey, Karolyn
    Montague, Riley C.
    Schadler, Aric D.
    Naseman, Kristina W.
    PHARMACOTHERAPY, 2025,
  • [25] Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 μG) with Robust Effects on Blood Glucose in Patients with T2DM
    Robertson, Darren
    Hansen, Lars
    Jain, Meena
    Parker, Victoria
    Petrone, Marcella
    Wang, Tao
    Heise, Tim
    Jermutus, Lutz
    DIABETES, 2020, 69
  • [26] Dual-acting peptide with prolonged GLP-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
    Claus, Thomas
    Pan, Clark
    Buxton, Joanne
    Tom, Irene
    Reynolds, Jennifer
    Barucci, Nicole
    Yang, Ling
    Burns, Michael
    Zhu, Jian
    Yung, Stephanie
    Milardo, Lucinda
    Ortiz, Astrid
    Roczniak, Steve
    Livingston, James
    Clairmont, Kevin
    Whelan, James
    DIABETES, 2006, 55 : A325 - A325
  • [27] GLP-1 for six weeks reduces weight and improves insulin sensitivity and glycemic control in patients with type 2 diabetes
    Zander, M
    Madsbad, S
    Holst, JJ
    DIABETES, 2001, 50 : A31 - A31
  • [28] Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of and Diabetes
    Palani, Anandan
    Nawrocki, Andrea R.
    Orvieto, Federica
    Bianchi, Elisabetta
    Mandic, Emanuela
    Pessi, Antonello
    Huang, Chunhui
    Deng, Qiaolin
    Toussaint, Nathalie
    Walsh, Erika
    Reddy, Vijay
    Ashley, Eric
    He, Huaibing
    Mumick, Sheena
    Hawes, Brian
    Marsh, Donald
    Erion, Mark
    Nargund, Ravi
    Carrington, Paul E.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (08): : 1248 - 1254
  • [29] ALBIGLUTIDE Glucagon-Like Peptide GLP-1 Receptor Agonist Treatment of Type 2 Diabetes
    Rosenstock, Julio
    Stewart, Murray W.
    DRUGS OF THE FUTURE, 2010, 35 (09) : 701 - 712
  • [30] Semaglutide GLP-1 receptor agonist Treatment of type 2 diabetes
    Chudleigh, R.
    Bain, S. C.
    DRUGS OF THE FUTURE, 2017, 42 (08) : 479 - 487
12345